Brought to you by 
Onyx signs second deal with Warner-Lambert
13 Jul 1999
Executive Summary
Warner-Lambert's Parke-Davis division will support Onyx Pharmaceuticals (research in intracellular signaling) with up to $30mm over three years in a program to discover new therapeutics to regulate inflammation and autoimmunity.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com